China's CataX AI has closed a RMB 40 million (USD 6 million) seed round exclusively backed and incubated by Qiming Venture Partners, launching an agent-native model for drug development founded in Shanghai in July 2026. The company targets the clinical-development bottleneck rather than early discovery, using specialised agents to run literature synthesis, document drafting and data handling while clinicians retain decision authority.
Its Clinical-of-One paradigm lets a single clinical lead orchestrate an entire programme, with project knowledge continuously captured and reused across assets. CataX plans to in-license or co-develop preclinical and early-stage candidates to proof-of-concept, betting that agent infrastructure lowers cycle time and cost more decisively than incremental trial-tooling.
The raise reflects investor conviction that AI's next margin of value in pharma lies not in generating molecules but in de-risking and accelerating the expensive, protocol-heavy path from first-in-human studies to registrational evidence.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation